Zdrowie i gospodarka · 07/08/1997
Duramed Pharmaceuticals and Barr Laboratories Face FDA Proposal to Refuse Approval of Conjugated Estrogens Tablets
The FDA is proposing to reject two abbreviated new drug applications for conjugated estrogens tablets, intended for menopause treatment and osteoporosis prevention, citing insufficient information about the active ingredients.
Source: Federal Register — Food and Drug AdministrationOpen original release →